Ryvu Therapeutics SA (RVU) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.553x

Based on the latest financial reports, Ryvu Therapeutics SA (RVU) has a cash flow conversion efficiency ratio of -0.553x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-22.84 Million ≈ $-6.29 Million USD) by net assets (zł41.33 Million ≈ $11.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RVU net asset quality index to measure how much of total assets are equity-financed.

Ryvu Therapeutics SA - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Ryvu Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check RVU cash flow quality score to evaluate the quality of earnings relative to operating cash generation.

Ryvu Therapeutics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ryvu Therapeutics SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
GREEN CROSS WellBeing Corporation KQ:234690	-0.037x
LI Ming Development Construction Co Ltd TWO:6212	-0.035x
Infant Bacterial Therapeutics AB (publ) ST:IBT-B	-0.420x
TK Chemical Corporation KQ:104480	0.005x
MCOT Public Company Limited F:OLU1	0.043x
Phinergy Ltd TA:PNRG	-0.265x
Team Precision Public Company Limited BK:TEAM	-0.034x
Shun On Electronic Co Ltd TW:6283	-0.025x

Annual Cash Flow Conversion Efficiency for Ryvu Therapeutics SA (2010–2025)

The table below shows the annual cash flow conversion efficiency of Ryvu Therapeutics SA from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see RVU market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł53.83 Million ≈ $14.82 Million	zł-114.10 Million ≈ $-31.40 Million	-2.119x	-135.52%
2024-12-31	zł143.88 Million ≈ $39.60 Million	zł-129.48 Million ≈ $-35.63 Million	-0.900x	-176.29%
2023-12-31	zł259.59 Million ≈ $71.44 Million	zł-84.55 Million ≈ $-23.27 Million	-0.326x	-624.62%
2022-12-31	zł343.39 Million ≈ $94.51 Million	zł21.32 Million ≈ $5.87 Million	0.062x	+118.18%
2021-12-31	zł169.42 Million ≈ $46.63 Million	zł-57.87 Million ≈ $-15.93 Million	-0.342x	-618.46%
2020-12-31	zł223.72 Million ≈ $61.57 Million	zł-10.64 Million ≈ $-2.93 Million	-0.048x	+67.28%
2019-12-31	zł119.76 Million ≈ $32.96 Million	zł-17.40 Million ≈ $-4.79 Million	-0.145x	+22.25%
2018-12-31	zł194.86 Million ≈ $53.63 Million	zł-36.42 Million ≈ $-10.02 Million	-0.187x	-208.91%
2017-12-31	zł64.00 Million ≈ $17.61 Million	zł10.98 Million ≈ $3.02 Million	0.172x	+252.23%
2016-12-31	zł55.71 Million ≈ $15.33 Million	zł-6.28 Million ≈ $-1.73 Million	-0.113x	+67.84%
2015-12-31	zł46.88 Million ≈ $12.90 Million	zł-16.43 Million ≈ $-4.52 Million	-0.350x	+33.84%
2014-12-31	zł9.25 Million ≈ $2.55 Million	zł-4.90 Million ≈ $-1.35 Million	-0.530x	+99.76%
2013-12-31	zł3.13 Million ≈ $861.02K	zł-694.94 Million ≈ $-191.26 Million	-222.129x	-13705.80%
2012-12-31	zł5.53 Million ≈ $1.52 Million	zł-8.90 Million ≈ $-2.45 Million	-1.609x	-208.42%
2011-12-31	zł11.46 Million ≈ $3.15 Million	zł-5.98 Million ≈ $-1.65 Million	-0.522x	+78.85%
2010-12-31	zł1.50 Million ≈ $413.48K	zł-3.71 Million ≈ $-1.02 Million	-2.467x	--

About Ryvu Therapeutics SA

WAR:RVU Poland Biotechnology

Market Cap

$93.79 Million

zł340.79 Million PLN

Market Cap Rank

#19360 Global

#154 in Poland

Share Price

zł14.74

Change (1 day)

-1.21%

52-Week Range

zł13.76 - zł30.95

All Time High

zł75.00